Mark R. Hake

Mark R. Hake

CFA

Mark R. Hake, CFA is a financial analyst and entrepreneur. He has been a Chartered Financial Analyst (CFA) for 31 years and has owned his own investment management and investment research firms that focused on value stocks, both in the U.S. and overseas.

Mark writes over 600 articles per year on stocks, cryptos, SPACs, convertibles, ETFs, and other financial securities. He has been ranked with 5 stars by TipRanks.com (under “Mark R. Hake”) with an average return of over 22% annually and #36 out of 8,116 writers. Presently he authors articles on Medium.com and other sites.

Mark also invests in public and private equities and has acted as a hedge fund manager and portfolio manager for various money management firms. He has also acted as CFO and Chief Strategy Officer for several fin-tech and software companies.

You can follow Mark on LinkedIn and on TipRanks.

Recent Articles

Genius Brands Has Transformed Into a Major Studio With Lots of Cash

By Mark R. Hake, CFA

Genius Brands has become a major kids' studio with lots of cash. But investors will want to see where that cash goes before buying GNUS stock.

Heavy Dilution From Cashless Warrants Is Forcing Naked Stock Down

By Mark R. Hake, CFA

Heavy dilution from cashless warrants is forcing NAKD stock down. NAKD stock will likely fall to 48 cents per share as hedge funds arbitrage the dilution.

Ethereum’s Value Premium Over Bitcoin Is Slowly Being Acknowledged

By Mark R. Hake, CFA

Ethereum skyrockets as its value premium over Bitcoin is slowly acknowledged. Ethereum will continue outperforming Bitcoin, due to its smart contract value.

Senseonics Stock Will Likely Rise on the Same Trajectory As DexCom

By Mark R. Hake, CFA

Senseonics will likely rise on the same trajectory as DexCom. SENS stock could rise 5 to 10 times over the next five years once it receives FDA approval.

Ideanomics Is Not Worth the Sum of Its Parts

By Mark R. Hake, CFA

Ideanomics now has a combination of EV-related and non-EV-related segments. Unfortunately, IDEX stock is not worth the sum of these parts.

Clover Health Is Stuck Sick In Bed Following Mediocre Q4 Results

By Mark R. Hake, CFA

Clover Health stock will languish while the insurer loses money. CLOV stock won't rebound until it can prove its business can turn a profit.

DoorDash Stock Is Ready for Delivery to Higher Levels

By Mark R. Hake, CFA

DoorDash stock is ready for pickup and delivery to higher levels. DASH stock could double over the next two to three years if sales keep pace.

Skillz Stock Looks Like It Has Got Plenty of Game and Upside Here

By Mark R. Hake, CFA

Skillz looks like it has got plenty of game and upside from here. SKLZ stock, despite the short attacks, could easily rebound 16%.

Expect Support Stock to Jump By More Than 50% From Its Merger

By Mark R. Hake, CFA

Support.com will be a next-gen Bitcoin miner with its Greenidge merger. Look for SPRT stock to move 50% higher as its merger date nears.

Cinedigm Believes Its NFTs Will Raise Its Value — But Will They?

By Mark R. Hake, CFA

CIDM stock is up due to the potential NFT value of its film library, but it's hard to know how to value those NFTs yet, so use caution.

Load More